Olr561 inhibitors represent a specialized class of chemical compounds that target and modulate the activity of the olfactory receptor 561 (Olr561). Olfactory receptors, including Olr561, are a subset of G-protein-coupled receptors (GPCRs) that are primarily responsible for detecting volatile odorant molecules, thus playing a critical role in the sense of smell. These receptors are characterized by their seven-transmembrane domain structure and their ability to activate intracellular signaling pathways upon binding to specific ligands. Inhibitors of Olr561 function by binding to the receptor, either competitively or allosterically, thereby preventing the receptor from interacting with its natural odorant ligands. This inhibition can lead to a disruption in the normal signal transduction processes, effectively altering the sensory perception mediated by Olr561.
Research into Olr561 inhibitors often focuses on understanding the molecular interactions between these inhibitors and the receptor. Structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to elucidate the binding sites and conformational changes induced by the inhibitors. Computational methods, including molecular docking and dynamics simulations, further complement these studies by predicting the energetics and stability of inhibitor-receptor complexes. These investigations not only provide insights into the fundamental mechanisms of olfactory signal modulation but also contribute to the broader understanding of GPCR function. The study of Olr561 inhibitors also intersects with organic chemistry, as the design and synthesis of these molecules involve sophisticated methodologies to ensure specificity and potency. Overall, the exploration of Olr561 inhibitors is a multidisciplinary endeavor that combines elements of biochemistry, structural biology, and computational chemistry to advance the knowledge of olfactory receptor regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
Inhibits CYP17, potentially affecting androgen synthesis and proteins in androgen signaling pathways. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
PI3K inhibitor, potentially altering proteins involved in the AKT/mTOR signaling pathway. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Inhibits histone deacetylases, potentially affecting gene expression and chromatin remodeling proteins. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits MET, VEGFR, and RET, potentially affecting proteins in multiple signaling pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Inhibits Bruton's tyrosine kinase, potentially affecting proteins in B-cell receptor signaling. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits cyclin-dependent kinases 4 and 6, potentially affecting cell cycle-related proteins. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
PARP inhibitor, potentially affecting proteins involved in DNA repair pathways. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
Inhibits EZH2, potentially affecting gene expression through histone methylation. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially influencing apoptosis-related proteins. | ||||||